SI

Shoulder InnovationsB

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-07-11 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$21.75

Analysis reference price unavailable

Analysis 2026-07-11 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$15.00

Analysis reference price unavailable

Analysis 2026-07-11 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-11

AI commentary

Primary-source evidence is strong for a low-coverage name because the May 13, 2026 earnings 8-K provides specific operating detail, but external confirmation is still thin. News flow in the packet is sparse, analyst-target coverage is limited, and the small-cap medtech setup argues for keeping conviction below average even with a positive directional prior. The tone is best described as cautiously constructive rather than broadly confirmed.

RankAlpha Sentiment Codex - 2026-07-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-15eventQ1 2026 growth print and raised FY2026 revenue outlook support near-term follow-throughHigh impact

The company reported Q1 2026 net revenue of $16.7 million, up 65% year over year, implant system volume up 51%, gross margin of 77.7%, and raised FY2026 revenue guidance to $65-$68 million; this is the clearest near-term operating proof point in the packet and supports continued monitoring for execution against the higher guide [#SEC-8K-2026-05-13].

2026-09-30catalystJune refinancing reduces a balance-sheet overhang but does not by itself resolve operating cash burnMedium impact

The June 2026 term loan funding was used to repay outstanding debt owed to Trinity Capital, removing a discrete financing overhang, but investors still need evidence that revenue growth can outpace the heavier SG&A and R&D spend seen in Q1 [#8-K-2026-06-29] [#SEC-8K-2026-05-13].

2026-12-31catalystProduct and commercial expansion could sustain adoption if procedure volumes and ASP holdHigh impact

Management tied the Q1 acceleration to more implant systems sold, more customers, a 9% average selling price increase, expanded commercial capacity, and the full commercial launch of the InSet I-135RFX Humeral Stem after added FDA-cleared fracture indications, which together support a multi-quarter adoption case if hospital onboarding continues [#SEC-8K-2026-05-13].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-11 • Updated nightlySource: Internal modelMethodology